An interventional study of High intensity exercise and Omega-3 fish oil in Obesity, Heart Failure, Diastolic and Metabolic Syndrome, sponsored by University of Texas Southwestern Medical Center. Completed at 1 site in United States. Open to participants aged 40 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-01-05.
Sponsored by University of Texas Southwestern Medical Center · Not applicable, Interventional, and Treatment
The purpose of this study is to determine whether 1 year of supervised exercise training in obese individuals at high risk for developing HF, incorporating high intensity interval training (HIIT) two to three times per week in conjunction with daily oral administration of omega-3 poly-unsaturated fatty acids will lead to reduction in visceral adiposity, regression of myocardial triglyceride levels and improvements in cardiac diastolic and vascular function.
The global objective of this project is to test novel strategies to prevent obesity related abnormalities in diastolic function that may progress to heart failure with preserved ejection fraction (HFpEF). These include: a) identifying high risk individuals by using population derived imaging and blood biomarkers; and b) implementing novel exercise training and "nutri-ceutical" strategies in obese middle aged individuals with high amounts of visceral fat, an important risk factor in the development of heart failure and adverse cardiac remodeling.
Prior work has demonstrated that: a) high levels of myocardial triglyceride content are associated with a smaller and less distensible left ventricle with reduced tissue relaxation rates compared to those with low levels and b) low fitness and high body mass index were the strongest predictors of elevated myocardial content. The consequences of excess visceral adiposity (intra- and retro-peritoneal adipose tissue) on cardiac remodeling suggest individuals with high visceral fat content and low fitness are at particularly high risk for heart failure.
The primary objective of this project is therefore to identify high risk, sedentary, middle aged obese individuals with high visceral fat levels, and initiate an exercise program in conjunction with omega-3 fatty acid supplementation designed to reduce visceral adiposity and regress myocardial triglyceride accumulation. Findings from this aim would have enormous public health significance and establish a novel, practical exercise training program and "nutria-ceutical" strategy to reverse obesity related cardiovascular remodeling.
Hypothesis:
High aerobic exercise training in conjunction with daily omega-3 supplementation will reduce visceral myocardial triglyceride accumulation by reducing visceral adiposity. A reduction of myocardial fat will lead to improved LV structure and diastolic function by an approach that is not necessarily predicated on weight loss.
Specific Aim:
To test our hypothesis that reduction in myocardial triglyceride content will improve markers of diastolic function, we have designed a randomized, double blind, placebo controlled trial. We will study four groups of previously sedentary obese middle aged subjects at high risk for development of HF for one year with the following interventions: A) sedentary controls taking placebo; B) sedentary subjects taking omega-3 fatty acids; C) subjects undergoing high intensity aerobic exercise training while on placebo and D) subjects undergoing high intensity aerobic exercise training while taking omega-3 fatty acids. Subjects will be categorized as high risk and enrolled on the basis of elevated serum biomarkers (cTnT) and high visceral fat content (>2.5 kg). We will perform comprehensive non-invasive assessments of cardiovascular structure and systolic/diastolic function before and after 1 year of an exercise intervention involving high intensity intervals and omega-3 administration. We anticipate the combination of high intensity aerobic exercise in conjunction with high dose omega-3 supplementation will reduce visceral adiposity, decrease myocardial triglyceride content and improve markers of diastolic and vascular function.
Exclusion Criteria:
Subjects randomized to control group will receive olive oil placebo capsules and yoga intervention for 1 year.
Behavioral: Yoga · Dietary Supplement: olive oil capsules
Subjects will receive high dose omega-3 fatty acids as well as aerobic exercise intervention for 1 year.
Behavioral: High intensity exercise · Dietary Supplement: Omega-3 fish oil
Subjects will receive high dose omega-3 fatty acids as well as yoga intervention for 1 year.
Dietary Supplement: Omega-3 fish oil · Behavioral: Yoga
Subjects will receive olive oil placebo as well as aerobic exercise intervention for 1 year.
Behavioral: High intensity exercise · Dietary Supplement: olive oil capsules
Subjects will be randomized to the exercise groups will undergo 1 year aerobic exercise training comprised of high intensity exercise sessions 2-3 days per week. Sessions will be supervised remotely via heart rate monitors.
Subjects randomized to omega-3 fatty acids will take 2 grams total of omega-3 per day for 1 year.
Subjects randomized to yoga will undergo yoga training as a control to those randomized to high intensity aerobic exercise.
Subjects randomized to receive olive oil placebo will take 1 gram total of olive oil capsule per day.
Change From Baseline at 1 Year in Myocardial Lipid Content
Myocardial triglyceride (lipid) content will be measured using cardiac nuclear magnetic resonance spectroscopy. We quantified the total myocardial triglyceride (TG) resonance from water-suppressed spectra. Myocardial TG content relative to water (%) as well as relative amounts of myocardial TG was calculated from the available data.
Time frame: Baseline, 1 year
Change From Baseline at 1 Year in Peak Volume of Oxygen (VO2)
Change in peak VO2 (normalized for body weight those who completed the study). Peak VO2 is a measure how well the heart and lungs are working during exercise.
Time frame: Baseline,1 year
Change From Baseline at 1 Year in Markers of Arterial Stiffness
Changes in arterial stiffness is measured using pulse-wave velocity (PWV) to look at intervention effects from baseline to 1 year in the control and treatment groups.
Time frame: Baseline, 1 year
Change From Baseline at 1 Year in Left Ventricular Mass
Change in left ventricular mass is measured by cardiac MRI to look at intervention effects from baseline to 1 year in the control and treatment groups.
Time frame: Baseline, 1 year
| Milestone | Control | Exercise and Omega-3 Fatty Acids | Yoga and Omega-3 Fatty Acids | Exercise Control |
|---|---|---|---|---|
| Started | 16 | 24 | 18 | 22 |
| Completed | 13 | 13 | 14 | 16 |
| Not completed | 3 | 11 | 4 | 6 |
Myocardial triglyceride (lipid) content will be measured using cardiac nuclear magnetic resonance spectroscopy. We quantified the total myocardial triglyceride (TG) resonance from water-suppressed spectra. Myocardial TG content relative to water (%) as well as relative amounts of myocardial TG was calculated from the available data.
| %fat/water | Control | Exercise and Omega-3 Fatty Acids | Yoga and Omega-3 Fatty Acids | Exercise Control |
|---|---|---|---|---|
| Change From Baseline at 1 Year in Myocardial Lipid Content | -0.16 ± 1.1 | -0.18 ± 0.59 | -0.53 ± 0.66 | -0.19 ± 0.42 |
Change in peak VO2 (normalized for body weight those who completed the study). Peak VO2 is a measure how well the heart and lungs are working during exercise.
| ml/kg/min | Control | Exercise and Omega-3 Fatty Acids | Yoga and Omega-3 Fatty Acids | Exercise Control |
|---|---|---|---|---|
| Change From Baseline at 1 Year in Peak Volume of Oxygen (VO2) | 0.21 ± 1.59 | 4.39 ± 2.48 | -0.03 ± 1.84 | 4.53 ± 2.65 |
Changes in arterial stiffness is measured using pulse-wave velocity (PWV) to look at intervention effects from baseline to 1 year in the control and treatment groups.
| cm/s | Control | Exercise and Omega-3 Fatty Acids | Yoga and Omega-3 Fatty Acids | Exercise Control |
|---|---|---|---|---|
| Change From Baseline at 1 Year in Markers of Arterial Stiffness | -15 ± 107 | -16 ± 80 | 32 ± 141 | -7 ± 104 |
Change in left ventricular mass is measured by cardiac MRI to look at intervention effects from baseline to 1 year in the control and treatment groups.
| grams | Control | Exercise and Omega-3 Fatty Acids | Yoga and Omega-3 Fatty Acids | Exercise Control |
|---|---|---|---|---|
| Change From Baseline at 1 Year in Left Ventricular Mass | 0.2 ± 7.7 | 7.2 ± 6.6 | -5.8 ± 10.4 | 6.0 ± 10 |
Collected over 1 year, during study period. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Control | 0/13 (0%) | 0/13 (0%) | 0/13 (0%) |
| Exercise and Omega-3 Fatty Acids | 0/13 (0%) | 0/13 (0%) | 0/13 (0%) |
| Yoga and Omega-3 Fatty Acids | 0/14 (0%) | 0/14 (0%) | 0/14 (0%) |
| Exercise Control | 0/16 (0%) | 0/16 (0%) | 0/16 (0%) |
| Age, Continuous(years) | Control | Exercise and Omega-3 Fatty Acids | Yoga and Omega-3 Fatty Acids | Exercise Control | Total |
|---|---|---|---|---|---|
| Mean | 49 ± 6 | 50 ± 6 | 47 ± 9 | 50 ± 6 | 49 ± 6 |
| Sex: Female, Male(Participants) | Control | Exercise and Omega-3 Fatty Acids | Yoga and Omega-3 Fatty Acids | Exercise Control | Total |
|---|---|---|---|---|---|
| Female | 11 | 15 | 10 | 12 | 48 |
| Male | 5 | 9 | 8 | 10 | 32 |
| Race (NIH/OMB)(Participants) | Control | Exercise and Omega-3 Fatty Acids | Yoga and Omega-3 Fatty Acids | Exercise Control | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 1 | 0 | 0 | 2 |
| Asian | 0 | 0 | 1 | 1 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 3 | 5 | 6 | 3 | 17 |
| White | 12 | 18 | 11 | 18 | 59 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| BMI(kg/m^2) | Control | Exercise and Omega-3 Fatty Acids | Yoga and Omega-3 Fatty Acids | Exercise Control | Total |
|---|---|---|---|---|---|
| Mean | 36.7 ± 5.2 | 36.7 ± 5.3 | 40.5 ± 6.5 | 36.7 ± 5.0 | 38.9 ± 5.7 |
Documents are hosted by the registry — open the source record to download them.
Plan to share: No
This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Texas Southwestern Medical Center